000			nab a22 7a 4500
999			_c17333 _d17333
003			PC17333
005			20230322135640.0
008			230322b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9388 _aLahuerta Palacios, Juan José _eHematología y Hemoterapia
245	0	0	_aRevised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. _h[artículo]
260			_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology, _c2015
300			_a33(26):2863-9.
500			_aFormato Vancouver: Palumbo A, Avet Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015 Sep 10;33(26):2863-9.
501			_aPMID: 26240224 PMC4846284
504			_aContiene 29 referencias
520			_aPurpose: The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and reliable tool is needed to stratify patients with MM. We combined the International Staging System (ISS) with chromosomal abnormalities (CA) detected by interphase fluorescent in situ hybridization after CD138 plasma cell purification and serum lactate dehydrogenase (LDH) to evaluate their prognostic value in newly diagnosed MM (NDMM). Patients and methods: Clinical and laboratory data from 4,445 patients with NDMM enrolled onto 11 international trials were pooled together. The K-adaptive partitioning algorithm was used to define the most appropriate subgroups with homogeneous survival. Results: ISS, CA, and LDH data were simultaneously available in 3,060 of 4,445 patients. We defined the following three groups: revised ISS (R-ISS) I (n = 871), including ISS stage I (serum β2-microglobulin level < 3.5 mg/L and serum albumin level ≥ 3.5 g/dL), no high-risk CA [del(17p) and/or t(4;14) and/or t(14;16)], and normal LDH level (less than the upper limit of normal range); R-ISS III (n = 295), including ISS stage III (serum β2-microglobulin level > 5.5 mg/L) and high-risk CA or high LDH level; and R-ISS II (n = 1,894), including all the other possible combinations. At a median follow-up of 46 months, the 5-year OS rate was 82% in the R-ISS I, 62% in the R-ISS II, and 40% in the R-ISS III groups; the 5-year PFS rates were 55%, 36%, and 24%, respectively. Conclusion: The R-ISS is a simple and powerful prognostic staging system, and we recommend its use in future clinical studies to stratify patients with NDMM effectively with respect to the relative risk to their survival.
710			_9297 _aServicio de Hematología y Hemoterapia
856			_uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846284/ _yAcceso libre
942			_2ddc _cART _n0